LIMA to LAD grafting returns patient survival to age-matched population: 20-year outcomes of MIDCAB surgery
Interactive CardioVascular and Thoracic Surgery · 09.09.2022 · 35 (4)
DOI: 10.1093/icvts/ivac243 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Interactive CardioVascular and Thoracic Surgery, online erschienen am 21.09.2022. Verfasst von Lucy Manuel und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cardiothoracic Surgery Department, Royal North Shore Hospital, St Leonards, Australia. Hauptthemen laut MEDLINE: Coronary Artery Bypass, Coronary Artery Disease. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
OBJECTIVES Previous studies have demonstrated the safety and excellent short-term and mid-term survival after minimally invasive direct coronary artery bypass (MIDCAB). We reviewed the long-term outcomes up to 20 years, including overall survival and freedom from reintervention. METHODS Consecutive patients who underwent MIDCAB between February 1997 and August 2020 were identified. Demographic details, operative information and long-term outcomes were obtained. The Australian National Death Index database was accessed to obtain long-term mortality data. RESULTS A total of 271 patients underwent an MIDCAB procedure during the study period. There were no intraoperative deaths and only one 30-day mortality (0.4%). The mean length of follow-up was 9.82 ± 8.08 years. Overall survival at 5-, 10-, 15- and 20-year survival was 91.9%, 84.7%, 71.3% and 56.5%, respectively. Patients with single-vessel disease [left anterior descending artery (LAD) only] had significantly better survival compared to patients with multivessel disease (P = 0.0035). During long-term follow-up, there were no patients who required repeat revascularization of the LAD territory. Sixty-nine patients died with the cause of death in 15 patients (21.7%) being attributable to ischaemic heart disease. An analysis comparing the isolated LAD disease MIDCAB cohort survival with the expected survival among an age/gender/year matched sample of the Australian reference population, using the standardized mortality ratio, demonstrated that the rate of survival returned to that of the reference population (standardized mortality ratio = 0.94). CONCLUSIONS MIDCAB is a safe and effective revascularization strategy which can be successfully performed in a carefully selected patient population with low morbidity and excellent long-term results. The survival of MIDCAB patients returns to that of their age/gender/year-matched counterparts within the normal population and hence should be offered as an alternative to coronary stenting when counselling patients with ischaemic heart disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cardiothoracic Surgery Department, Royal North Shore Hospital, St Leonards, Australia.
- Cardiothoracic Surgery Department, Prince of Wales Hospital, Randwick, Australia.
- School of Public Health, Curtin University, Perth, Australia.
ORCID-Profile: Lucy Manuel
Zitieren
APA
Manuel, L., Fong, L. S., Betts, K., Bassin, L., & Wolfenden, H. (2022). LIMA to LAD grafting returns patient survival to age-matched population: 20-year outcomes of MIDCAB surgery. Interactive CardioVascular and Thoracic Surgery, 35(4). https://doi.org/10.1093/icvts/ivac243
Vancouver
Manuel L, Fong LS, Betts K, Bassin L, Wolfenden H. LIMA to LAD grafting returns patient survival to age-matched population: 20-year outcomes of MIDCAB surgery. Interactive CardioVascular and Thoracic Surgery. 2022;35(4). doi:10.1093/icvts/ivac243
BibTeX
@article{Manuel2022,
author = {Manuel, Lucy and Fong, Laura S and Betts, Kim and Bassin, Levi and Wolfenden, Hugh},
title = {LIMA to LAD grafting returns patient survival to age-matched population: 20-year outcomes of MIDCAB surgery},
journal = {Interactive CardioVascular and Thoracic Surgery},
year = {2022},
volume = {35},
number = {4},
doi = {10.1093/icvts/ivac243}
}
EUVIMED